Catalyst Pharmaceutical
CPRX
97 hedge funds and large institutions have $193M invested in Catalyst Pharmaceutical in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 14 closing their positions.
103% more call options, than puts
Call options by funds: $928K | Put options by funds: $458K
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
14% more capital invested
Capital invested by funds: $169M → $193M (+$23.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 99 → 97 (-2)
3.07% less ownership
Funds ownership: 52.82% → 49.75% (-3.1%)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$3.45M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.05M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$820K |
| 4 |
BlackRock
New York
|
+$602K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$580K |
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$5.13M |
| 2 |
Millennium Management
New York
|
-$4.62M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$2.26M |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$1.52M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$148K | -47,400 | Closed |
|
|
ECM
102
Element Capital Management
New York
| – | -$146K | -46,868 | Closed |
|
|
CS
103
Credit Suisse
Zurich,
Switzerland
| – | -$78K | -25,048 | Closed |
|
104
Two Sigma Investments
New York
| – | -$68K | -21,673 | Closed |
|
|
AB
105
Amalgamated Bank
New York
| – | -$46K | -14,892 | Closed |
|
106
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$39.8K | -12,695 | Closed |
|
107
SG Americas Securities
New York
| – | -$39K | -12,576 | Closed |
|
|
LTFS
108
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$5K | -2,000 | Closed |
|
|
SFM
109
Signet Financial Management
Parsippany,
New Jersey
| – | -$6K | -2,000 | Closed |
|
|
PIA
110
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$5K | -1,675 | Closed |
|
111
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$3K | -1,000 | Closed |
|
CPRX Hedge Fund Activity: Q3 2018 in Review
97 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2018, worth a combined $193M — up 14% from $169M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CPRX and 12 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 35 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $3.45M. The largest seller was Broadfin Capital, cutting an estimated $5.13M.
- 97 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2018, down from 99 in Q2 2018.
- Funds reported $193M of Catalyst Pharmaceutical stock for Q3 2018, up 14% quarter-over-quarter.
- 12 funds opened new Catalyst Pharmaceutical positions in Q3 2018 and 14 closed out, a net change of -2 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2018 was OrbiMed, an estimated $3.45M added.
- The largest Catalyst Pharmaceutical seller in Q3 2018 was Broadfin Capital, an estimated $5.13M sold.
Based on aggregated 13F filings for Q3 2018.